AU550774B2 - 1-aryl-2-aminomethyl cyclopropane carboxylates - Google Patents

1-aryl-2-aminomethyl cyclopropane carboxylates

Info

Publication number
AU550774B2
AU550774B2 AU85086/82A AU8508682A AU550774B2 AU 550774 B2 AU550774 B2 AU 550774B2 AU 85086/82 A AU85086/82 A AU 85086/82A AU 8508682 A AU8508682 A AU 8508682A AU 550774 B2 AU550774 B2 AU 550774B2
Authority
AU
Australia
Prior art keywords
atom
aryl
alkyl group
lower alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU85086/82A
Other languages
English (en)
Other versions
AU8508682A (en
Inventor
Bernard Bonnaud
Henri Cousse
Michel Morre
Gilbert Mouzin
Antoine Stenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9259785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU550774(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre SA filed Critical Pierre Fabre SA
Publication of AU8508682A publication Critical patent/AU8508682A/en
Application granted granted Critical
Publication of AU550774B2 publication Critical patent/AU550774B2/en
Assigned to PIERRE FABRE S.A. reassignment PIERRE FABRE S.A. Alteration of Name(s) in Register under S187 Assignors: PIERRE FABRE S.A.
Assigned to PIERRE FABRE MEDICAMENT reassignment PIERRE FABRE MEDICAMENT Alteration of Name(s) in Register under S187 Assignors: PIERRE FABRE S.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU85086/82A 1981-06-23 1982-06-22 1-aryl-2-aminomethyl cyclopropane carboxylates Expired AU550774B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8112312A FR2508035A1 (fr) 1981-06-23 1981-06-23 Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
FR8112312 1981-06-23

Publications (2)

Publication Number Publication Date
AU8508682A AU8508682A (en) 1983-01-06
AU550774B2 true AU550774B2 (en) 1986-04-10

Family

ID=9259785

Family Applications (1)

Application Number Title Priority Date Filing Date
AU85086/82A Expired AU550774B2 (en) 1981-06-23 1982-06-22 1-aryl-2-aminomethyl cyclopropane carboxylates

Country Status (11)

Country Link
US (1) US4478836A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0068999B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS584752A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE13422T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU550774B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1202639A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3263734D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8303293A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2508035A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU90410I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA824453B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
FR2581060B1 (fr) * 1985-04-25 1988-07-01 Pf Medicament Procede industriel d'obtention du midalcipran
US5621142A (en) * 1994-02-22 1997-04-15 Asahi Kasei Kogyo Kabushiki Kaisha Aminoalkylcyclopropane derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
CA2462903C (en) * 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
CA2503381A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
SI1601349T1 (sl) * 2003-02-14 2008-10-31 Pf Medicament Uporaba enantiomera milnaciprana za pripravo zdravila
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
EP1620083A2 (en) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Combination therapies
EP1656349B1 (en) * 2003-08-15 2011-10-12 H. Lundbeck A/S Cyclopropyl derivatives as nk3 receptor antagonists
JP4713474B2 (ja) * 2003-08-15 2011-06-29 ハー・ルンドベック・アクチエゼルスカベット Ｎｋ３受容体アンタゴニストとしてのシクロプロピル誘導体
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
AR056979A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofuranos y usos de los mismos
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
US7402687B2 (en) * 2005-04-22 2008-07-22 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2006132307A1 (ja) 2005-06-10 2006-12-14 Pierre Fabre Medicament S.A. 安定化されたミルナシプラン製剤
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2640451C (en) * 2006-01-27 2011-09-13 Asahi Kasei Pharma Corporation Medicine for transnasal administration
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2008104957A2 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Novel polymorphic forms of milnacipran hydrochloride
US20090048233A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010036773A1 (en) * 2008-09-24 2010-04-01 Concert Pharmaceuticals, Inc. Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
FR2941454B1 (fr) 2009-01-29 2011-04-01 Pf Medicament Proced de synthese du (1s,2r)-milnacipran
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100274050A1 (en) * 2009-04-23 2010-10-28 Glenmark Generics Limited Solid milnacipran and process for the preparation of the same
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
MX2012001393A (es) 2009-08-05 2012-08-03 Lupin Ltd Composiciones farmacéuticas de liberación controlada de milnacipran.
EP2496079A4 (en) 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
WO2011092065A1 (en) 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
ES2858499T3 (es) 2010-07-01 2021-09-30 Azevan Pharmaceuticals Inc Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
JP2013536832A (ja) 2010-08-30 2013-09-26 ルピン・リミテッド ミルナシプランの制御放出医薬組成物
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
WO2012145234A2 (en) * 2011-04-21 2012-10-26 Emory University Cyclopropyl derivatives and methods of use
WO2014009767A1 (en) 2012-07-07 2014-01-16 Micro Labs Limited An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
WO2014203277A2 (en) * 2013-06-19 2014-12-24 Msn Laboratories Private Limited Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
WO2015044962A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited Amorphous form of levomilnacipran hydrochloride and hydrates thereof
SG10202001065SA (en) 2014-03-28 2020-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
EP3681871A4 (en) 2017-09-15 2021-05-26 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BRAIN DAMAGE
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA619080A (en) * 1961-04-25 The Upjohn Company N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES
CA570688A (en) * 1959-02-17 E. Speeter Merrill Antispasmodic substituted amines
GB1415541A (en) * 1972-11-30 1975-11-26 Hexachimie 1-amino-methyl-2,2-diarylcyclopropanecarboxamide

Also Published As

Publication number Publication date
US4478836A (en) 1984-10-23
ES512842A0 (es) 1983-03-01
ZA824453B (en) 1983-04-27
DE3263734D1 (en) 1985-06-27
JPS584752A (ja) 1983-01-11
JPS6323186B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-05-16
FR2508035A1 (fr) 1982-12-24
AU8508682A (en) 1983-01-06
CA1202639A (fr) 1986-04-01
ATE13422T1 (de) 1985-06-15
FR2508035B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-06-29
EP0068999A1 (fr) 1983-01-05
LU90410I2 (fr) 1999-08-31
EP0068999B1 (fr) 1985-05-22
ES8303293A1 (es) 1983-03-01

Similar Documents

Publication Publication Date Title
AU550774B2 (en) 1-aryl-2-aminomethyl cyclopropane carboxylates
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
NZ238181A (en) N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions
ES8103744A1 (es) Un metodo para la preparacion de derivados de ftalimidina
PT76450A (de) Spiro/4.(3+n)-2-aza-3-carbonsaeure-derivate verfahren zu ihrer herstellung diese enthaltende mittel und ihre verwendung
ES538418A0 (es) Un derivado de indol-3-carboxamida
DK519985D0 (da) Quinoloncarboxylsyrederivater, fremgangsmaade til fremstilling deraf og antibakterielt middel indeholdende saadanne derivater
DE3882438D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
FI101301B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahydroatsepiinijohdannaisten valmistamiseksi
ES544417A0 (es) Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas.
PT93450A (pt) Processo para a preparacao de novos derivados azetidinicos de acidos piridinocarboxilicos e de composicoes farmaceuticas que os contem
ES8307205A1 (es) Un procedimiento para la preparacion de-amino acidos n-sustituidos.
DK469285A (da) Thiadiazolderivater, der indvirker paa centralnervesystemet, fremgangsmaade til fremstilling deraf og midler indeholdende derivaterne
ES8307798A1 (es) Un procedimiento para la preparacion de derivados de piperazilmetil-4-dibenzofuranona, o, dibenzofuranol.
AU1621392A (en) New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them
IT1261958B (it) 2-(sostituite immino)-tiazolidine e procedimento per la loro preparazione e loro impiego quali antianginose e/o analgesiche

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired